WNK2 and cancer: Studies have demonstrated that JAG1 signaling in cancer cells can activate downstream pathways such as AP-1 (activator protein 1), MAPK (mitogen-activated protein kinases), EGFR (epidermal growth factor receptor), and NF-κB [27, 35–37].